Key Players
Competitive Landscape
Four supplier models compete in sustainable drug manufacturing: integrated pharmaceutical groups, full-service CDMOs, biologics capacity specialists and process-equipment or analytical-system providers. In-house groups set product and network standards. CDMOs execute sponsor processes, biologics specialists add qualified capacity and technology providers supply continuous processing or monitoring systems.
Investment has moved in two directions since 2025: toward renewable electricity for existing networks and toward new capacity designed with lower resource intensity. Thermo Fisher Scientific signed a 10-year VPPA in February 2025 for a 73 MW share expected to generate about 150,000 MWh annually. Samsung Biologics opened its 180,000-liter Plant 5 in April 2025. A July 2025 company update reported a design carbon footprint 20% below earlier facilities. Price remains relevant, but sponsors screen manufacturers first for validated process control, site environmental performance and dependable technology transfer.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Thermo Fisher Scientific signed a 10-year VPPA on February 4, 2025. Its 73 MW share is expected to generate about 150,000 MWh annually. | Drug manufacturers need renewable electricity across multi-site supply chains without building generation at every site. | Pharmaceutical companies are aggregating power demand to secure larger renewable projects and share procurement expertise. | Renewable-power contracting and lower-carbon CDMO services gain revenue from companies facing Scope 2 and Scope 3 requirements. |
| Samsung Biologics opened its 180,000-liter Plant 5 in April 2025. In July 2025, the company reported a design carbon footprint 20% below previous facilities. | Biologics sponsors need additional capacity without proportionate growth in energy and water use. | New CDMO plants are embedding environmental controls during design instead of retrofitting established operations. | Efficient biologics capacity can attract sponsors that compare carbon and water data during partner selection. |
| GSK's Nashik facility received the BSI Kitemark for Minimized Risk of AMR on October 13, 2025. | Antibiotic purchasers need evidence that manufacturing controls reduce antimicrobial discharge risks. | Site-level environmental certification is entering manufacturing qualification for antibiotic supply. | Certified antibiotic production and wastewater-control services can secure customers with responsible-manufacturing standards. |
AstraZeneca plc, Pfizer Inc., Novartis AG, Roche Holding AG, Merck & Co., Inc., Sanofi and Lonza Group AG compete on qualification depth and application expertise outside the three developments summarized in the table.
Source: Future Market Insights, Sustainable Drug Manufacturing Market, 2026-2036.
Thermo Fisher Scientific and Samsung Biologics together cover renewable-power procurement, small- and large-molecule services, biologics capacity and site environmental systems while GSK's Nashik facility holds the BSI AMR Kitemark and Lonza reports GMP operations across audited in-scope manufacturing sites.
Who leads the sustainable drug manufacturing market?
Competitive position varies by manufacturing route rather than one verified universal share. AstraZeneca and Sanofi maintain broad in-house programs, while Lonza, Samsung Biologics and Thermo Fisher compete through outsourced capacity and technology transfer.
Which suppliers have documented environmental or manufacturing approvals?
GSK's Nashik facility holds the BSI Kitemark for Minimized Risk of AMR. Samsung Biologics lists ISO 14001 and ISO 50001, while Lonza reports that in-scope manufacturing sites operate under GMP standards and receive health-authority audits.
Which companies provide biologics contract manufacturing?
Lonza's 2025 annual report covers mammalian, microbial, bioconjugate and drug-product services. Samsung Biologics provides large-scale mammalian manufacturing, while Thermo Fisher provides pharmaceutical services through Patheon.
Which suppliers serve North America and Europe?
Lonza reports more than thirty global development and manufacturing sites. Thermo Fisher provides pharmaceutical services in North America and Europe, while AstraZeneca, Pfizer, Novartis, Roche, Merck, GSK and Sanofi use internal networks across both regions.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| AstraZeneca plc | Global in-house manufacturing network | Green chemistry, process mass intensity and continuous processing across small-molecule development. |
| Pfizer Inc. | Global in-house manufacturing network | Green chemistry, continuous processing and supplier climate requirements across its manufacturing network. |
| Novartis AG | Global in-house manufacturing network | Green chemistry, solvent recovery, biologics and small-molecule manufacturing. |
| Roche Holding AG | Global in-house manufacturing network | CustomBiotech production and biomass-generated process steam at the Penzberg site. |
| Merck & Co., Inc. | Global in-house manufacturing network | Green chemistry, renewable electricity and manufacturing-resource targets across global operations. |
| GSK plc | Global in-house manufacturing network | Antibiotic manufacturing and site-level AMR controls at the Nashik facility. |
| Sanofi | Global in-house manufacturing network | Vaccines and medicines using eco-design, life-cycle assessment and process mass intensity. |
| Lonza Group AG | Global CDMO network | Small and large molecules, mammalian and microbial biologics, bioconjugates, drug products and technology transfer. |
| Samsung Biologics Co., Ltd. | South Korea and United States CDMO footprint | Mammalian biologics, ADC services and 784,000-liter capacity following Plant 5. ISO 14001 and ISO 50001 cover environmental and energy management. |
| Thermo Fisher Scientific Inc. | North American and European pharmaceutical-services network | Pharmaceutical services through Patheon plus renewable electricity procurement for European operations. |
Research Methodology
The companies in this section illustrate market structure rather than a ranking. Inclusion requires current evidence that a company manufactures drugs, provides CDMO services or supplies manufacturing systems with measurable environmental controls. Evidence comes from official annual reports, sustainability disclosures, filings, dated company releases and certification records. Site certifications belong to the entity or facility that holds them. The 58.0% small-molecule figure is an FMI estimate for 2026.
